Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eitan Amir

Showing results (1-10 of 349) with videos related to

Pageof 35
Sort By:
The Lancet. Oncology|February 3, 2019
Endpoint selection in HER2-positive early breast cancerEitan Amir
The Lancet. Oncology|December 5, 2018
Competing risks of extended adjuvant aromatase inhibitorsEitan Amir
Journal of Thoracic Disease|June 1, 2018
Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancerHabeeb Majeed, Eitan Amir
The Lancet. Oncology|October 3, 2009
Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?Eitan Amir, Mark Clemons
Cancer Treatment Reviews|September 8, 2009
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directionsAlberto Ocaña, Eitan Amir
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?Paaladinesh Thavendiranathan, Eitan Amir
European Journal of Cancer (Oxford, England : 1990)|April 11, 2015
Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practiceAmirrtha Srikanthan, Eitan Amir
British Journal of Cancer|February 23, 2018
EQUATOR-Oncology: reducing the latitude of cancer trial design and reportingHabeeb Majeed, Eitan Amir
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Underestimation of risk by Gail model extends beyond women with atypical hyperplasiaEitan Amir, Orit Freedman
Translational Cancer Research|December 19, 2024
The next frontier in breast cancer: genomic co-alteration and its impact on biology and treatment planningMeredith Li, Eitan Amir
Pageof 35

Showing results (1-10 of 349) with videos related to

Sort By:
Pageof 35
The Lancet. Oncology|February 3, 2019
Endpoint selection in HER2-positive early breast cancerEitan Amir
The Lancet. Oncology|December 5, 2018
Competing risks of extended adjuvant aromatase inhibitorsEitan Amir
Journal of Thoracic Disease|June 1, 2018
Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancerHabeeb Majeed, Eitan Amir
The Lancet. Oncology|October 3, 2009
Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?Eitan Amir, Mark Clemons
Cancer Treatment Reviews|September 8, 2009
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directionsAlberto Ocaña, Eitan Amir
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?Paaladinesh Thavendiranathan, Eitan Amir
European Journal of Cancer (Oxford, England : 1990)|April 11, 2015
Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practiceAmirrtha Srikanthan, Eitan Amir
British Journal of Cancer|February 23, 2018
EQUATOR-Oncology: reducing the latitude of cancer trial design and reportingHabeeb Majeed, Eitan Amir
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Underestimation of risk by Gail model extends beyond women with atypical hyperplasiaEitan Amir, Orit Freedman
Translational Cancer Research|December 19, 2024
The next frontier in breast cancer: genomic co-alteration and its impact on biology and treatment planningMeredith Li, Eitan Amir
Pageof 35